Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Novo Nordisk A S NVO

7 fiscal years on record · DKK · FY2025 reported · SEC filings only
DKK 309.1B
▲ 6.4% YoY
DKK 102.4B
▲ 1.4% YoY
DKK 59.0B
▼ 20.1% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Novo Nordisk manufactures and markets pharmaceutical products and services. Its products include glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes, and modern and human insulins for the treatment of diabetes. Headquartered in Denmark, it employs more than 69,500 people in around 80 countries and markets its products in approximately 170 countries. Novo Nordisk has two business segments, Obesity and Diabetes care and Rare disease. For the treatment of obesity it markets three drugs: Saxenda®, Wegovy® in injectable formats, and Wegovy® Pill. Wegovy® has been launched in the United States and more than 50 other countries outside the United States. Global sales of Ozempic® were more than DKK 127 billion in 2025. Its Rare disease portfolio consists mainly of growth hormone and haemophilia products.

Written from the business description in NOVO NORDISK A S's annual report to the U.S. Securities and Exchange Commission, filed 4 February 2026. Every sentence was checked against that document before publication.

Growth

DKK 309.1B
Revenue, FY2025 · full 7-year series below
Revenue DKK B Net income DKK B
FY2025 · Revenue 309.1 · Net income 102.4
150B300B
201920222025
Compound annual growth
+20.4%
+19.5%
+22.6%
+19.4%
+2.5%
+7.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.5% a year over the five years to FY2025 — but profit grew slower: net income at +19.4%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

33 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 41.3% · Net 33.1%
20%40%
201920222025
ROE
FY2025 · ROE 60.7%
50%
201920222025
Three returns, three denominators.

Each DKK of equity produced 61 cents of profit this year.

Cash & shareholders

DKK 53.2B
returned in FY2025 · dividends + net buybacks
Free cash flow DKK B
FY2025 · FCF 59.0
30B60B
201920222025
Net buybacks DKK B Dividends DKK B
FY2025 · Dividends 51.8 · Net buybacks 1.4
25.0B50.0BDividendsNet buybacks
2019202020212022202320242025
Dividends paidDKK 51.8B
Net buybacksDKK 1.4B
Share of profit51.9%
Consecutive raises2 years (since the 2023 share-count change)

DKK 51.8B in dividends and DKK 1.4B in buybacks — 52% of the year's profit went back to shareholders.

Total assetsDKK 542.9B
CashDKK 26.5B
Gross debtDKK 131.0B
Net debtDKK 104.5B
Current ratio0.80×

Net debt stands at 54% of equity.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · DKK

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NVO, 7-year financial record
Metric 2025202420232022202120202019
Revenue DKK B309.1290.4232.3177.0140.8126.9122.0
Operating income DKK B127.7128.3102.674.858.654.152.5
EBITDA DKK B142.3136.9109.981.464.759.958.1
Income tax DKK B28.126.221.013.511.311.09.6
Net income DKK B102.4101.083.755.547.842.139.0
Free cash flow DKK B59.073.883.166.748.746.137.9
EPS, diluted DKK 23.0322.6318.6212.2210.3718.0116.38
Dividend / sh DKK 11.7011.409.406.2010.409.10◌
Payout %51443846454850
ROE %60.780.888.172.071.269.767.6
Shares out B4.444.444.462.282.312.352.40

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image